U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 16

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with letter dated August 23, 2010
1. Mercy Medical Center	3. License number 11-27089-01 is amended in its entirety to read as follows:
2. 1512 12th Avenue Road Nampa, Idaho 83686-6008	4. Expiration date April 30, 2012
	5. Docket No. 030-32246 Reference No.

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 300 millicuries

9. Authorized use:

A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.

B. Any imaging and localization study permitted by 10 CFR 35.200.

C. Any use permitted by 10 CFR 35.300.

CONDITIONS

10. Licensed material may be used or stored only at the licensee's facilities located at 1512 12th Avenue Road, Nampa, Idaho.

11. The Radiation Safety Officer for this license is Daniel John Wegner, M.D.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
11-27089-01

Docket or Reference Number
030-32246

Amendment No. 16

12. Licensed material is only authorized for use by, or under the supervision of:

A. Individuals permitted to work as an authorized user, authorized nuclear pharmacist, and/or authorized medical physicist in accordance with 10 CFR 35.13 and 35.14.

B. The following individuals are authorized users for the material and medical uses indicated:

Authorized Users	Material and Use
Murali N. Bathina, M.D.	35.100; 35.200
Andrew U. Chai, M.D.	35.100; 35.200
James Field, M.D.	35.100; 35.200
Neil Couchman Davey, M.D.	35.100; 35.200; Gadolinium-153 for attenuation correction
Scott R. Hiatt, D.O.	35.100; 35.200
Michael D. Kenner, M.D.	35.100; 35.200
Randolph Cotton Byrd, M.D.	35.100; 35.200
Carolyn Ely Coffman, M.D.	35.100; 35.200; Gadolinium-153 for attenuation correction
Jeffrey Wayne Grossman, M.D.	35.100; 35.200; Oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries
Vicken Garabedian, M.D.	35.100; 35.200
Janice Allison Brooks, M.D.	35.100; 35.200; 35.300
Jeffrey T. Hall, M.D.	35.100; 35.200
William Murray, M.D.	35.100; 35.200
John Truksa, M.D.	35.100; 35.200; 35.300
Dallas D. Peck, M.D.	35.100; 35.200
Daniel John Wegner, M.D.	35.100; 35.200; 35.300
Bertram Jason Stremmler, M.D.	35.100; 35.200; Oral administration of sodium iodide I-131
William Taylor, M.D.	35.100; 35.200; Oral administration of sodium iodide I-131
Michael J. Ryan, M.D.	35.100; 35.200; Oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries
Curtis Coulam, M.D.	35.100; 35.200; 35.300
Ian Davey, M.D.	35.100; 35.200; 35.300; Gadolinium-153 for attenuation correction

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
11-27089-01

Docket or Reference Number
030-32246

Amendment No. 16

Authorized Users	Material and Use
Anthony P. Giauque, M.D.	35.100; 35.200; 35.300
Reginald Joseph Gobel, M.D.	35.100; 35.200; 35.300
John Q. Knochel, M.D.	35.100; 35.200; 35.300
Jason Patrick Silber, M.D.	35.100; 35.200; 35.300
Lisa M. Scales, M.D.	35.100; 35.200; 35.300
Howard B. Schaff, M.D.	35.100; 35.200; 35.300
Jeffrey Seabourn, M.D.	35.100; 35.200; 35.300
Rodger W. Shaver, M.D.	35.100; 35.200; 35.300
Loreli S. Smith, M.D.	35.100; 35.200; 35.300

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing financial assurance for decommissioning.

14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, “Packaging and Transportation of Radioactive Material.”

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
11-27089-01

Docket or Reference Number
030-32246

Amendment No. 16

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated December 20, 2001 [ML020070537]
B. Facsimile dated March 22, 2002 [ML021070746]
C. Facsimile dated April 10, 2002 [ML021070746]
D. Letter dated February 17, 2010 [ML100670522]

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date November 5, 2010

By **/RA/**

Roberto J. Torres, Senior Health Physicist
Nuclear Materials Safety Branch B
Region IV
Arlington, Texas 76011-4125